Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP1246323.RA1Jp6_WjUynWlWbFYjXQ7nnwpgc2Br-GY2LoV6_mWxh4130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP1246323.RA1Jp6_WjUynWlWbFYjXQ7nnwpgc2Br-GY2LoV6_mWxh4130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP1246323.RA1Jp6_WjUynWlWbFYjXQ7nnwpgc2Br-GY2LoV6_mWxh4130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP1246323.RA1Jp6_WjUynWlWbFYjXQ7nnwpgc2Br-GY2LoV6_mWxh4130_provenance.
- NP1246323.RA1Jp6_WjUynWlWbFYjXQ7nnwpgc2Br-GY2LoV6_mWxh4130_assertion description "[Human epidermal growth factor receptor 2 (HER2) overexpression is present in approximately 15% of early invasive breast cancers, and is an important predictive and prognostic marker.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1246323.RA1Jp6_WjUynWlWbFYjXQ7nnwpgc2Br-GY2LoV6_mWxh4130_provenance.
- NP1246323.RA1Jp6_WjUynWlWbFYjXQ7nnwpgc2Br-GY2LoV6_mWxh4130_assertion evidence source_evidence_literature NP1246323.RA1Jp6_WjUynWlWbFYjXQ7nnwpgc2Br-GY2LoV6_mWxh4130_provenance.
- NP1246323.RA1Jp6_WjUynWlWbFYjXQ7nnwpgc2Br-GY2LoV6_mWxh4130_assertion SIO_000772 25488926 NP1246323.RA1Jp6_WjUynWlWbFYjXQ7nnwpgc2Br-GY2LoV6_mWxh4130_provenance.
- NP1246323.RA1Jp6_WjUynWlWbFYjXQ7nnwpgc2Br-GY2LoV6_mWxh4130_assertion wasDerivedFrom befree-2016 NP1246323.RA1Jp6_WjUynWlWbFYjXQ7nnwpgc2Br-GY2LoV6_mWxh4130_provenance.
- NP1246323.RA1Jp6_WjUynWlWbFYjXQ7nnwpgc2Br-GY2LoV6_mWxh4130_assertion wasGeneratedBy ECO_0000203 NP1246323.RA1Jp6_WjUynWlWbFYjXQ7nnwpgc2Br-GY2LoV6_mWxh4130_provenance.
- befree-2016 importedOn "2016-02-19" NP1246323.RA1Jp6_WjUynWlWbFYjXQ7nnwpgc2Br-GY2LoV6_mWxh4130_provenance.